Federal contract award
HT942524F0020
EXPERIMENTAL THERAPEUTICS RESEARCH SUPPORT
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Defense |
| Office | ARMY MED RES ACQ ACTIVITY |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | 47QRAD20D4012 |
| Set-aside | Not reported |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $7.1M |
| Current contract value | $8.4M |
| Potential contract value / ceiling | $22.4M |
| Start date | Jan 27, 2024 |
| Current end date | Jul 31, 2026 |
| Potential end date | Jul 31, 2028 |
| Latest award activity | Feb 13, 2026 |
| Source loaded | Sep 19, 2026 |
Funding and modification history
Showing the latest 12 of 12 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Feb 13, 2026 | P00016 | $75.0K | NEW DRUG DISCOVERY AND DEVELOPMENT OF NOVEL THERAPEUTICS TO COMBAT OR OTHERWISE TREAT SPECIFIC BIOLOGICAL AND/OR ENVIRONMENTAL THREATS TO THE WARFIGHTER. |
| Nov 21, 2025 | P00015 | $332.1K | NEW DRUG DISCOVERY AND DEVELOPMENT OF NOVEL THERAPEUTICS TO COMBAT OR OTHERWISE TREAT SPECIFIC BIOLOGICAL AND/OR ENVIRONMENTAL THREATS TO THE WARFIGHTER. |
| Sep 2, 2025 | P00014 | $1.0K | NEW DRUG DISCOVERY AND DEVELOPMENT OF NOVEL THERAPEUTICS TO COMBAT OR OTHERWISE TREAT SPECIFIC BIOLOGICAL AND/OR ENVIRONMENTAL THREATS TO THE WARFIGHTER. |
| Aug 13, 2025 | P00013 | $427.4K | NEW DRUG DISCOVERY AND DEVELOPMENT OF NOVEL THERAPEUTICS TO COMBAT OR OTHERWISE TREAT SPECIFIC BIOLOGICAL AND/OR ENVIRONMENTAL THREATS TO THE WARFIGHTER. |
| Jul 15, 2025 | P00012 | $65.0K | NON-PERSONAL SERVICES FOR RESEARCH SUPPORT FOR DRUG DISCOVERY |
| Jul 10, 2025 | P00011 | $346.0K | NON-PERSONAL SERVICES FOR RESEARCH AND SUPPORT FOR DRUG DEVELOPMENT |
| Jun 10, 2025 | P00010 | $215.0K | DEPARTMENT OF DRUG DEVELOPMENT SUPPORT SERVICES FOR IDENTIFICATION, CHARACTERIZATION, AND DEVELOPMENT OF NEW DRUGS TO PROTECT THE WARFIGHTER |
| Apr 25, 2025 | P00009 | $-8.0K | DEPARTMENT OF DRUG DEVELOPMENT SUPPORT SERVICES FOR WARFIGHTER. |
| Mar 28, 2025 | P00008 | $-299.8K | EXPERIMENTAL THERAPEUTICS TO ENSURE HEALTH, ENDURANCE, AND COMBAT EFFECTIVENESS OF WARFIGHTERS |
| Feb 20, 2025 | P00007 | $865.5K | THIS REQUIREMENT IS FOR NONPERSONAL SUPPORT SERVICES FOR THE DEPARTMENT OF DRUG DEVELOPMENT WITHIN THE EXPERIMENTAL THERAPEUTICS BRANCH LOCATED AT THE WALTER REED ARMY INSTITUTE OF RESEARCH. |
| Jan 17, 2025 | P00006 | $184.8K | EXPERIMENTAL THERAPEUTICS AND DRUG DEVELOPMENT |
| Oct 28, 2024 | P00005 | $354.5K | THIS REQUIREMENT IS FOR SUPPORT SERVICES FOR THE DEPARTMENT OF DRUG DEVELOPMENT. |
Estimated positioning window
Jul 31, 2027 – Jan 31, 2028
65/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 65/100. Available recorded signals: 60 points.
- Contract end 2028-07-31 (638 days from calculation)
- +25 points
- 99 historical awards in this buyer and category group
- +15 points
- 12 recorded award transactions
- +10 points
- Latest award action: 2026-02-13
- +5 points
- Parent award identifier recorded
- +5 points
- Solicitation identifier recorded
- +0 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-11-01 10:17:53.997580+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Nov 1, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Verify whether remaining options may extend performance beyond the current end date.
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.